摘要
目的探讨1^(131)Ⅰ-Rituximab经瘤内注射对荷人Burkitts淋巴瘤细胞系Raji细胞移植瘤裸鼠放射免疫治疗疗效。方法 ^(131)Ⅰ标记物的标记采用IODO-GEN碘化标记;按预定治疗方案分别注入含有131I标记物,开始治疗前及治疗后每天用游标卡尺测量肿瘤长、短径,计算肿瘤体积,依公式计算肿瘤生长抑制率。结果 ^(131)Ⅰ-Rituximab瘤内注射组肿瘤抑制率显著高于腹腔注射组、^(131)Ⅰ-IgG瘤内注射组以及对照细胞组(P<0.05);^(131)Ⅰ-Rituximab不同剂量瘤内注射,小剂量组肿瘤生长抑制率低于大剂量组,但差异无统计学意义(P>0.05)。结论 ^(131)Ⅰ-Rituximab经瘤内途径给药可以获得更好的放射免疫治疗效果,为下一步临床应用奠定了基础。
Objective To investigate the therapeutic efficacy of radioimmunotherapy of iodine-131 labeled Rituximab using intratumor injection（IT）in nude mice with xenografted raji cells tumor.Methods Iodine-131 labeled Rituximab was carried out by IODO-GEN method.The nude mice bearing raji cells tumor were divided into six groups based on the injected marked-drugs.The size of the tumor was measured every 2～3 day and the inhibition rates of different groups were calculated.Results The tumor inhibition rates of ^（131）Ⅰ-Rituximab IT group were higher than those of IP group,^（131）Ⅰ-IgG IT group and cell control group（P0.05）.^（131）Ⅰ-Rituximab with intratumor injection in different dose showed that inhibition rate of low dose group was lower than that of high group,while there was no significant difference（P0.05）.Conclusion Iodine-131 labeled Rituximab with intratumor injection showed the highest radioimmunotherapy efficacy which offered the experimental evidence for clinical application in the futrue.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
2011年第1期35-37,44,共4页
Cancer Research on Prevention and Treatment
基金
广东省医学科研基金资助项目(B2009158)
关键词
^131Ⅰ
抗CD20单克隆抗体
淋巴瘤
瘤内注射
Iodine-131
Anti-CD20 monoclonal antibody
Non-Hodgkin＇s lymphoma（NHL）
Intratumor injection
